Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
121 Clinical Trials near Miami, FL
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Combination Vaccine for Flu and COVID-19
Miami, FloridaThis study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
780 Participants Needed
Cetuximab + Bevacizumab for Brain Tumor
Miami, FloridaThis study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:1 - 21
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Lactation, Significant Medical Conditions, Others
20 Participants Needed
Orca-Q for Pediatric Leukemia
Miami, FloridaThis is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:< 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior HCT, Active Infections, HIV, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants
40 Participants Needed
Flu Vaccine for Influenza
Coral Gables, FloridaThe purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
1158 Participants Needed
Flu and COVID-19 Vaccines for Virus Protection
Miami, FloridaThis study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
1353 Participants Needed
ITU512 for Sickle Cell Disease
Miami, FloridaThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Arrhythmias, Significant Illness, Others
Must Not Be Taking:Hydroxyurea
161 Participants Needed
Flu Vaccine for Adults
Miami, FloridaThis trial is testing new mRNA flu vaccines in adults aged 18 and older. The vaccines work by using genetic instructions to help the body recognize and fight the flu virus. The study aims to see if these new vaccines are safe and effective. The first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses were evaluated for safety and effectiveness over a period of several years.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
910 Participants Needed
Pneumococcal Vaccine for Pneumococcal Disease
Coral Gables, FloridaThis trial is testing different versions of a pneumococcal vaccine to see if they are safe and effective. It involves adults aged 18-49 in the initial phase and adults aged 50 and older in the later phase. The vaccine helps the immune system fight off pneumococcal bacteria. A newer version of the vaccine is designed to protect against 20 different types of bacteria.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
418 Participants Needed
This trial is testing a new vaccine that protects against five types of meningococcal bacteria in adults and adolescents. The vaccine helps the body learn to fight off these bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:10 - 25
Sex:All
1220 Participants Needed
C. difficile Vaccine for C. difficile Infection
Miami, FloridaAn antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff). Three new formulations of the C. diff vaccine will be used in this study, in addition to a C. diff vaccine formulation that has been studied in previous clinical trials.
The purpose of this study is to understand if giving the new C. diff vaccine formulations helps people make as many antibodies as giving the previously studied C. diff vaccine formulation.
The study is divided into 2 phases.
Phase 1 will evaluate 3 new formulations of the C. diff vaccine and 2 dosing schedules spread out over 2 months or 6 months.
The Phase 1 portion of the study is seeking participants:
* who are healthy adults of 65 to 84 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
All participants in Phase 1 will receive study injections with active vaccine or placebo at each vaccination visit, depending on the vaccine group to which they are assigned. A placebo does not contain any active ingredients. Participants in Phase 1 will attend at least 9 study visits and will take part in the study for approximately 18 months. Based on the results of Phase 1, 1 or 2 of the new C. diff vaccine formulations will be chosen for further study in Phase 2.
Phase 2 will evaluate the safety and effects of the new C. diff vaccine formulation(s) chosen in Phase 1.
The Phase 2 portion of the study is seeking participants:
* who are healthy adults ≥65 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
Phase 2 participants will receive active C. diff vaccine or placebo at each vaccination visit. Participants in Phase 2 will attend at least 6 and up to 12 study visits and will take part in the study for up to 4 years.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:65 - 84
Sex:All
689 Participants Needed
ALN-KHK for Type 2 Diabetes
Miami, FloridaThis trial is testing a new drug called ALN-KHK to see how safe it is and how the body processes it. They are also testing another drug called KHK to check its safety and effectiveness. The study targets patients who might benefit from these drugs, aiming to understand their safety and how they work in the body.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
49 Participants Needed
BMF-219 for Type 2 Diabetes
Miami, FloridaThis trial tests a new pill called BMF-219 that targets a protein named menin. It includes healthy adults and those with Type 2 Diabetes to see if it helps control blood sugar levels.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
414 Participants Needed
Flu and COVID-19 Vaccines for Coronavirus and Influenza
Miami, FloridaThe purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.
This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
2050 Participants Needed
This is a Phase I, Single-Center, Open-Label study evaluating the safety and pharmacokinetics of single doses of ZID-FEP and metronidazole alone or in combination utilizing a 3-period, crossover study design. Thirty eligible male and female healthy adult subjects will participate in the study and receive single doses of (1) ZID-FEP 3g IV (ZID 1 g plus FEP 2 g) administered over 1 hour (h); (2) metronidazole 0.5 g IV alone administered over 1 h; and (3) metronidazole 0.5 g IV over 1 h, followed by ZID-FEP 3g IV over 1 h over 3 treatment periods separated by a 48 h washout period.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, CNS, Respiratory, Others
Must Not Be Taking:NSAIDs, Sucralfate, Others
30 Participants Needed
CAB ULA for HIV Infection
Coral Gables, FloridaThis study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Respiratory, HIV, Hepatitis, Others
Must Not Be Taking:Anti-coagulants
60 Participants Needed
ALG-097558 for Coronavirus
Miami, FloridaThis is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Drug Abuse, Alcohol Use, Others
16 Participants Needed
Oxycodone and Nafamostat for Pharmacokinetics
Miami, FloridaA single and multiple-dose dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release(ER) capsule prototypes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Renal, Hepatic, Others
Must Not Be Taking:Aspirin, NSAIDs, Anticoagulants, Others
50 Participants Needed
LY4100511 Absorption Study
Miami, FloridaThe main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
48 Participants Needed
Lepodisiran for Liver Dysfunction
Miami, FloridaThe main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants.
The study will last up to approximately 9 weeks, excluding screening.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 85
Sex:All
33 Participants Needed
RBM-001 for Coronavirus
Miami, FloridaA First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
60 Participants Needed
Quizartinib for Liver Disease
Miami, FloridaThis study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Primary Biliary Cirrhosis, Gilbert's Syndrome, Others
12 Participants Needed
BMS-986278 for Kidney Failure
Miami, FloridaThe purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 84
Sex:All
Key Eligibility Criteria
Disqualifiers:Significant Medical Condition, Pregnancy, Others
32 Participants Needed
Olomorasib for Liver Failure
Miami, FloridaThe main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Metabolic, Gastrointestinal, Cardiovascular, Others
Must Not Be Taking:Prescription Medications
48 Participants Needed
EBV Vaccine for Healthy Adults
Miami, FloridaEpstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 30
Sex:All
Key Eligibility Criteria
Disqualifiers:Infectious Mononucleosis, Immunosuppressive Conditions, Others
Must Not Be Taking:Immunosuppressants
200 Participants Needed
AJ302-IM for Healthy Volunteers
Miami, FloridaThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AJ302-IM following intramuscular administration of single ascending doses in healthy volunteers.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Suicidal Ideation, HIV, Hepatitis, Others
56 Participants Needed
LY3537031 for Obesity
Miami, FloridaThis is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.
Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 20 weeks excluding a screening period.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:22 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bariatric Surgery, Lactating, High Calcitonin, Others
Must Not Be Taking:Weight Loss Drugs
230 Participants Needed
AMG 513 for Obesity
Miami, FloridaThe primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
80 Participants Needed
MK-2060 Safety Study in Healthy Participants
Miami, FloridaThe goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 50
Sex:All
64 Participants Needed
NMRA-323511 for Agitation in Alzheimer's Disease
Miami, FloridaThis study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.
Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Epilepsy, Suicidal, Neurologic Disorder, Others
Must Not Be Taking:Anticonvulsants
96 Participants Needed
PGT121.414.LS + VRC07-523LS for HIV
Miami, FloridaThe purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:< 72
Sex:All
48 Participants Needed
Page 1 of 5+
Frequently Asked Questions
How much do clinical trials in Miami, FL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials in Miami, FL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study in Miami, FL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials in Miami, FL ?
Most recently, we added Cetuximab + Bevacizumab for Brain Tumor, SRP-3D for Pain Management and PGT121.414.LS + VRC07-523LS for HIV to the Power online platform.